Patents by Inventor Dale Grabowski

Dale Grabowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOAVAILABLE PROTEIN DISULFIDE ISOMERASE INHIBITORS
    Publication number: 20230312552
    Abstract: Compounds according to formula (I) are described wherein R1 is an amino acid or a modified amino acid linked to the compound through a peptide bond, R2 is selected from CN, SO2CH3, NO2, CO2R3, CONHR3, NH2, NMe2 and CF3, and R3 is selected from H or lower alkyl, X is O or S, and Y is C—H or N, or a pharmaceutically acceptable salt thereof. The compounds can be used as protein disulfide isomerase inhibitors. The compounds can also be used in a method of treating or cancer in a subject.
    Type: Application
    Filed: August 27, 2021
    Publication date: October 5, 2023
    Inventors: Babal K. Jha, James G. Phillips, Frederic J. Reu, Metis Hasipek, Dale Grabowski, Jaroslaw P. Maciejewski
  • ANTITUMOR NAPHTHALENYL BENZAMIDE DERIVATIVES
    Publication number: 20170057910
    Abstract: Naphthalenyl benzamide derivatives according to formula I are described, wherein Ar is an aryl or heteroaryl group, and R1-R4 are independently selected from H, halogen, CF3, hydroxyl, C1-C4 alkyl, and C1-C4 oxyalkyl, or a pharmaceutically acceptable salt thereof. The naphthalenyl benzamide derivatives can be used for the treatment of cancer in a subject.
    Type: Application
    Filed: August 29, 2016
    Publication date: March 2, 2017
    Inventors: Frederic J. Reu, Sergei Vatolin, James G. Phillips, Dale Grabowski, Babal Kant Jha
  • Protein disulfide isomerase inhibiting anticancer agents
    Patent number: 9359342
    Abstract: Protein disulfide isomerase inhibitors according to formula I are described, wherein R1 is an aryl or cycloalkyl group, R2 is selected from the group consisting of CN, SO2CH3, NO2, CO2R3, CONHR3, NMe2, and CF3, R3 is selected from H or lower alkyl, R4 is H, halogen, CN, or COOH, and X and Y are C—H or heteroatoms selected from the group consisting of N, O, and S. The protein disulfide isomerase inhibitors can be used for the treatment of cancer in a subject.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: June 7, 2016
    Assignee: The Cleveland Clinic Foundation
    Inventors: Frederic J. Reu, Jim Phillips, Sergei Vatolin, Dale Grabowski
  • PROTEIN DISULFIDE ISOMERASE INHIBITING ANTICANCER AGENTS
    Publication number: 20150133514
    Abstract: Protein disulfide isomerase inhibitors according to formula I are described, wherein R1 is an aryl or cycloalkyl group, R2 is selected from the group consisting of CN, SO2CH3, NO2, CO2R3, CONHR3, NMe2, and CF3, R3 is selected from H or lower alkyl, R4 is H, halogen, CN, or COOH, and X and Y are C—H or heteroatoms selected from the group consisting of N, O, and S. The protein disulfide isomerase inhibitors can be used for the treatment of cancer in a subject.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Inventors: Frederic J. Reu, Jim Phillips, Sergei Vatolin, Dale Grabowski